Resveratrol-Copper Combination Shows Promise Against Glioblastoma in Early Clinical Trial
Key Insights
A combination of resveratrol and copper supplements demonstrated significant biological activity against glioblastoma (search) tumors in a small 20-patient study conducted at ACTREC (search) in Mumbai, India.
The treatment reduced tumor growth activity by 33%, cancer biomarkers by 57%, and stem-cell markers by 56% without reported side effects over 12 days of treatment.
Researchers observed near-complete eradication of cell-free chromatin particles (search), which are key drivers of tumor aggressiveness in glioblastoma (search) patients.
Scientists at the Advanced Center for Treatment, Research and Education in Cancer (search) (ACTREC (search)) in Mumbai, India, have reported promising early results from a novel approach to treating glioblastoma (search), the most aggressive form of brain cancer (search). In a small clinical study published in BJC Reports in September, researchers found that a combination of resveratrol and copper supplements produced significant biological changes in tumor tissue without reported side effects.
Study Design and Methodology
The research team, led by Dr. Indraneel Mittra, conducted a controlled study involving 20 glioblastoma (search) patients scheduled for brain surgery. Ten patients received tablets containing resveratrol and copper four times daily for approximately 12 days before their operation, while the remaining 10 served as untreated controls. During surgery, doctors collected tumor tissue from all participants to enable direct comparison between treated and untreated tumors.
The samples underwent comprehensive analysis to measure tumor growth, inflammation, immune activity, cancer stem-cell markers, and the presence of cell-free chromatin particles (search)—DNA fragments released by dying cancer cells that can worsen tumor behavior.
Significant Biological Changes Observed
The treatment group demonstrated substantial improvements across multiple tumor markers. Tumor growth activity decreased by approximately 33%, while cancer biomarkers dropped by 57%. Immune-checkpoint signals fell by 41%, and stem-cell markers were reduced by 56%, according to the study press release.
"We observed near-complete eradication of cell-free chromatin particles (search) from the cancerous glioblastoma (search) tissues following the resveratrol and copper treatment," Mittra told Fox News Digital. "This finding was particularly significant because cell-free chromatin particles are key drivers of tumor aggressiveness."
Mechanism of Action
The researchers paired resveratrol and copper based on their synergistic mechanism. Copper enables resveratrol to generate reactive molecules that break down DNA debris known to inflame cancer cells. Resveratrol, a polyphenol found in red grapes and berries, has demonstrated antioxidant effects in previous research but reacted differently when combined with copper, helping to dissolve harmful DNA fragments.
"These results suggest that a simple, inexpensive and non-toxic nutraceutical tablet potentially has the power to heal glioblastoma (search)," Mittra stated.
Paradigm Shift in Cancer Treatment Philosophy
The findings challenge conventional cancer treatment approaches that focus on destroying malignant cells. "We have been trying to kill cancer cells for 2,500 years, since the time of the ancient Greeks, without success," Mittra explained. "Maybe it is time to look at cancer treatment differently and work toward healing tumors rather than annihilating them."
Mittra expressed optimism about the potential implications: "I believe we may be on the brink of transforming the way cancer is treated."
Study Limitations and Cautionary Notes
The researchers acknowledged several important limitations. The study involved only 20 patients and examined short-term changes in tumor tissue over just 12 days of treatment. The tumors' appearance did not change, and the supplements' interaction with standard treatments remains unclear. Most critically, it remains uncertain whether these biological changes translate to improved patient outcomes.
"The public should understand that ours is only a first step, and our findings are based on a relatively small number of patients, which needs replication in larger patient cohorts," Mittra cautioned. "They should not start self-medicating simply because these items are readily available. There may be minimal benefit unless the controlled formulation we designed for our study is used."
Regulatory and Safety Considerations
The Tata Memorial Center (search), which oversees ACTREC (search), issued a statement in 2024 emphasizing caution regarding early resveratrol-copper findings. The statement clarified that "resveratrol plus copper, including its tablet formulation, is not a substitute for established cancer treatments like surgery, radiotherapy, chemotherapy, hormone therapy and targeted therapy, which have been conclusively proven to provide benefits and result in cures in a substantial proportion of patients."
The American Cancer Society notes that while supplements are widely available, they can pose risks for cancer patients and should only be used under medical supervision. Research has shown that dietary supplements do not have proven anti-cancer effects, may disrupt diagnostic testing, and can involve uncertain safety profiles and potential interactions.
Future Research Directions
Larger, longer, and carefully controlled trials are needed to determine whether resveratrol and copper are safe for extended use and whether they truly improve glioblastoma (search) outcomes. Mittra and his team have been exploring this research direction for more than a decade, suggesting a sustained commitment to developing this experimental approach.
The research represents an early but potentially significant step toward alternative cancer treatment strategies, though substantial additional investigation is required before any clinical applications can be considered.